Kisho

Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy

osteonecrosis of the jaw (ONJ) - Clinical Profile, Genes & Research | Kisho | Kisho

Rare Disease

osteonecrosis of the jaw

MONDO:0018378

Also known as:ONJjaw osteonecrosisosteonecrosis of jaw

Find Clinical TrialsTrials

Overview

An area of necrotic bone in the mandible or maxilla.

TreatmentsNo approved treatments · 1 in pipeline

Clinical Trials13 registered · 4 recruiting

Diagnosis

Biomarker and diagnostic research for osteonecrosis of the jaw has been reported in the published literature.

Treatment

Compiled from FDA-approved drug records, orphan drug designations, and FDA Adverse Event Reporting System (FAERS) safety data. GeneReviews management guidance is included where available.

No approved treatments are currently available for osteonecrosis of the jaw. An additional 1 compound holds orphan drug designation.

Orphan Drug Designations

While no drugs are FDA-approved specifically for osteonecrosis of the jaw, some of the following designated compounds may be used off-label in clinical practice. Treatment decisions should be made in consultation with a specialist familiar with this condition.

The following drugs have received orphan drug designation from the FDA for osteonecrosis of the jaw. Orphan designation reflects regulatory interest and does not indicate approval for treatment.

Brand Name	Generic Name	Sponsor

Research Landscape

Sourced from ClinicalTrials.gov and PubMed. Publication types are classified using NLM-curated article metadata; research type breakdowns reflect the nature of published work for this disease.

13 clinical trials registered, 4 recruiting. Interventions under study include other interventions, procedural interventions, medical devices, and drug therapy. Pipeline includes 1 PHASE3, 1 PHASE2, 5 NA. Research is primarily sponsored by academic and government institutions.

NCT ID	Title	Phase	Sponsor	Status
[NCT05795647](https://clinicaltrials.gov/study/NCT05795647)

Data assembled from 5 of 12 sources · Last updated Sep 20, 2026, 8:44 AM UTC

MONDOHPOClinicalTrials.govFDAPubMedHGNCClinVarClinGenGeneReviewsOrphanetOMIMRUSP

Medical References

External Resources

Orphanet

European rare disease database

Orphanet:399293

GARD

Genetic and Rare Diseases Info Center

GARD:21663

Questions for Your Care Team

→Are any of the 13 active clinical trials a good fit for my situation?
→What is the current development status of Recombinant human platelet derived growth factor BB, and when might it become available?
→Are there specialists or centers of excellence for this condition in my area?
→Is there a patient registry I should consider joining?

← Back to All Diseases

Research Type	Count	% of Total
Research summaries	50	45%
Disease patterns and progression	22	20%
Laboratory research	18	16%
Clinical study results	10	9%
Patient case studies	6	5%
Testing and diagnosis research	3	3%
New treatment approaches	3	3%

Kisho

osteonecrosis of the jaw

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

External Resources

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

A Case of Capitate Osteonecrosis in a Patient With Thalassemia.

A rare osteonecrosis Kienböck's disease potentially linked to COVID-19: a case report.

Engineered Exosomal miR-146a-5p Reprograms BMSC Fate and Restores Mitochondrial Homeostasis in Glucocorticoid-Induced Osteonecrosis of Femoral Head.

osteonecrosis of the jaw

Overview

Diagnosis

Treatment

Orphan Drug Designations

Research Landscape

Medical References

External Resources

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

Clinical Trials

Recent Publications

Latest News & Developments

A Case of Capitate Osteonecrosis in a Patient With Thalassemia.

A rare osteonecrosis Kienböck's disease potentially linked to COVID-19: a case report.

Engineered Exosomal miR-146a-5p Reprograms BMSC Fate and Restores Mitochondrial Homeostasis in Glucocorticoid-Induced Osteonecrosis of Femoral Head.